Improved diagnostic efficiency is achieved with age-adjusted PSAD, balancing sensitivity and specificity effectively.
A-PSAD reduces false positives, leading to fewer unnecessary prostate biopsies and improved outcomes.
Validation involved constructing and testing a nomogram to enhance personalized screening for prostate cancer.
The findings support the use of age-adjusted PSAD in clinical settings, promoting better screening practices.
Abstract
A-PSAD offers a better balance between sensitivity and specificity compared to PSAD, reducing false positives and unnecessary biopsies, and presents a promising tool for personalized PCa screening.